Thompson Siegel & Walmsley LLC Buys 274,756 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Thompson Siegel & Walmsley LLC lifted its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 37.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,003,041 shares of the company’s stock after acquiring an additional 274,756 shares during the quarter. Henry Schein makes up approximately 1.1% of Thompson Siegel & Walmsley LLC’s holdings, making the stock its 24th biggest position. Thompson Siegel & Walmsley LLC owned about 0.80% of Henry Schein worth $73,122,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HSIC. Cromwell Holdings LLC boosted its stake in shares of Henry Schein by 93.4% in the third quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock worth $26,000 after acquiring an additional 170 shares during the period. Summit Securities Group LLC bought a new stake in shares of Henry Schein during the second quarter valued at approximately $31,000. Beach Investment Counsel Inc. PA purchased a new position in shares of Henry Schein in the second quarter worth $37,000. Blue Trust Inc. lifted its holdings in shares of Henry Schein by 104.2% in the second quarter. Blue Trust Inc. now owns 931 shares of the company’s stock worth $60,000 after buying an additional 475 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its stake in Henry Schein by 58.9% during the third quarter. Farther Finance Advisors LLC now owns 933 shares of the company’s stock valued at $68,000 after acquiring an additional 346 shares in the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on HSIC shares. StockNews.com upgraded Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. UBS Group decreased their price target on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Evercore ISI boosted their target price on shares of Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a report on Tuesday, October 8th. Barrington Research reaffirmed an “outperform” rating and issued a $82.00 price target on shares of Henry Schein in a report on Wednesday, November 6th. Finally, Robert W. Baird decreased their price objective on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $78.89.

Insider Buying and Selling

In other news, SVP Lorelei Mcglynn sold 21,035 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the transaction, the senior vice president now directly owns 71,833 shares in the company, valued at $4,978,026.90. This trade represents a 22.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Michael S. Ettinger sold 12,240 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the completion of the transaction, the chief operating officer now owns 87,706 shares in the company, valued at approximately $6,577,950. This trade represents a 12.25 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

Henry Schein Trading Down 1.5 %

Shares of NASDAQ HSIC opened at $73.73 on Thursday. Henry Schein, Inc. has a twelve month low of $63.67 and a twelve month high of $82.63. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The business has a fifty day simple moving average of $70.68 and a two-hundred day simple moving average of $69.69. The firm has a market cap of $9.19 billion, a PE ratio of 30.34, a price-to-earnings-growth ratio of 2.15 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.05. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm’s quarterly revenue was up .4% on a year-over-year basis. During the same period in the prior year, the business posted $1.32 EPS. Analysts expect that Henry Schein, Inc. will post 4.78 earnings per share for the current fiscal year.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.